SEC investigating Cassava Sciences, developer of experimental Alzheimer’s drug
The Securities and Exchange Commission is investigating claims that Cassava Sciences Inc., the sixth-best performing U.S. stock this year, manipulated research results of its experimental Alzheimers drug, according to people familiar with the matter.
Cassava…
